Cathelicidins as novel therapeutic antiviral agents in Rhinovirus infection

We have identified the human cathelicidn LL-37 as having potent direct antiviral activity against human rhinovirus (HRV), together with the capacity to alter death pathways in HRV-infected cells, as a potential host defence mechanism. We propose to characterise the mechanism by which LL-37 exerts antiviral effects towards HRV, and to access the potential for both exogenous LL-37 and Vitamin D to be used as antiviral therapeutics in this infection.

Start Date:

1 May 2015
End Date:

30 June 2017
Activity Type:

Externally Funded Research
Funder:

Chief Scientists Office
Value:

£163152